NEPHROPLUS

Nephrocare Health Services Share Price

 

 

Start SIP in NEPHROPLUS

Start SIP
Nephrocare Health Services live price: ₹563.85. It opened at ₹549 vs previous close ₹552; intraday high/low: ₹574/₹549. The 50 DMA stands at ₹523.90.

Nephrocare Health Services Performance

  • Low
  • ₹549
  • High
  • ₹574
  • 52 Week Low
  • ₹446
  • 52 Week High
  • ₹616
  • Open Price₹549
  • Previous Close₹552
  • Volume53,444
  • 50 DMA₹523.90
  • 100 DMA-
  • 200 DMA-

Investment Returns

  • Over 1 Month + 8.44%
  • Over 3 Month + 22.58%
  • Over 6 Month + 22.58%
  • Over 1 Year + 22.58%

Smart Investing Starts Here Start SIP with Nephrocare Health Services for Steady Growth!

Invest Now

Nephrocare Health Services Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 5,658
  • P/B Ratio
  • 7.8
  • Average True Range
  • 26.57
  • EPS
  • 7.11
  • Dividend Yield
  • 0
  • MACD Signal
  • 18.04
  • RSI
  • 52.93
  • MFI
  • 65.4

Nephrocare Health Services Financials

Nephrocare Health Services Technicals

EMA & SMA

Current Price
₹563.85
+ 11.55 (2.09%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 5
  • 20 Day
  • ₹561.65
  • 50 Day
  • ₹523.90
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

562.32 Pivot Speed
  • R3 600.73
  • R2 587.42
  • R1 575.63
  • S1 550.53
  • S2 537.22
  • S3 525.43

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Fresenius Medical Care operates as an integrated renal care company, combining the manufacture of dialysis products with the delivery of dialysis services.

Nephrocare Health Services Ltd has an operating revenue of Rs. 2,055.20 Cr. on a trailing 12-month basis. An annual revenue growth of 34% is outstanding, Pre-tax margin of 12% is healthy, ROE of 11% is good. The company has a reasonable debt to equity of 17%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 5% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 10% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 6 indicates it belongs to a strong industry group of Medical-Outpnt/Hm Care and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nephrocare Health Services Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-10 Quarterly Results

Nephrocare Health Services F&O

Nephrocare Health Services Shareholding Pattern

63.85%
3.1%
1.52%
9.3%
0.08%
5.92%
16.23%

About Nephrocare Health Services

  • NSE Symbol
  • NEPHROPLUS
  • BSE Symbol
  • 544647
  • Chairman & Managing Director
  • Mr. Vikram Vuppala
  • ISIN
  • INE428V01029

Similar Stocks to Nephrocare Health Services

Nephrocare Health Services FAQs

Nephrocare Health Services share price is ₹563 As on 07 March, 2026 | 04:34

The Market Cap of Nephrocare Health Services is ₹5657.7 Cr As on 07 March, 2026 | 04:34

The P/E ratio of Nephrocare Health Services is As on 07 March, 2026 | 04:34

The PB ratio of Nephrocare Health Services is 7.8 As on 07 March, 2026 | 04:34

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23